Marinus Pharma (MRNS) Tops Q1 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 12, 2022 4:04 PM EDTZTALMY® (ganaxolone) U.S. commercial launch on track for July 2022 Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected second half 2023 Site activations advance in Phase 3 TrustTSC trial in tuberous sclerosis complex; topline data anticipated first quarter 2024 Patient dosing underway for Phase 1 trial of ganaxolone second generation formulation; topline data on track for mid-2022 readout Continue to strengthen cash position with Oaktree Capital drawdown and expectation to monetize priority review voucher Marinus to host conference call today at 4:05 p.m.... More
